NICE recommends CINQAERO® (reslizumab) for the treatment of severe eosinophilic asthma

21st July 2017 Uncategorised 0

Teva Pharmaceutical Industries

More: NICE recommends CINQAERO® (reslizumab) for the treatment of severe eosinophilic asthma
Source: MDlinx